ZIOP Share Price

Open 6.26 Change Price %
High 6.50 1 Day 0.16 2.55
Low 6.06 1 Week -0.78 -10.80
Close 6.44 1 Month 1.23 23.61
Volume 1370772 1 Year -5.75 -47.17
52 Week High 11.49
52 Week Low 4.45
ZIOP Important Levels
Resistance 2 6.85
Resistance 1 6.68
Pivot 6.33
Support 1 6.20
Support 2 6.03
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

ZIOPHARM Oncology Inc (NASDAQ: ZIOP)

ZIOP Technical Analysis 3
As on 2nd Dec 2016 ZIOP Share Price closed @ 6.44 and we RECOMMEND Buy for LONG-TERM with Stoploss of 6.38 & Buy for SHORT-TERM with Stoploss of 5.90 we also expect STOCK to react on Following IMPORTANT LEVELS.
ZIOP Target for December
1st Target up-side 7.94
2nd Target up-side 8.96
3rd Target up-side 9.97
1st Target down-side 5.04
2nd Target down-side 4.02
3rd Target down-side 3.01
ZIOP Other Details
Segment EQ
Market Capital 370786624.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.ziopharm.com
ZIOP Address
ZIOP
Parris Building
Suite 34
Boston, MA 02129
United States
Phone: 617-259-1970
Fax: 617-241-2855
Interactive Technical Analysis Chart ZIOPHARM Oncology Inc ( ZIOP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ZIOPHARM Oncology Inc
ZIOP Business Profile
ZIOPHARM Oncology, Inc., is a biotechnology company. The Company employs gene expression and control technology to deliver deoxyribonucleic acid (DNA) for the treatment of cancer. The Company's technology employs Intrexon Corporation's RheoSwitch Therapeutic System to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. As of October 18, 2013, the technology was being evaluated in Phase II clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The Company is also developing small molecules as potential cancer therapeutics.